1 Apr 2015
CatSci is pleased to announce that it has been awarded two new grants for Early Stage Feasibility Studies following the Innovate UK Industrial Biotechnology Catalyst Round 2 call. In both cases, the new technology has the potential to significantly reduce manufacturing costs whilst concomitantly allowing an increased output of the nutraceutical with a more robust supply chain. Additionally, this will have the added benefit of generating a more sustainable process as it will be more energy efficient and less reliant on hydrocarbon and precious metal based technologies.
A collaboration bewteen Prozomix and CatSci has been established as part of the Innovate UK’s IB Catalyst. The key goal of the 12-month project is to develop a technology platform for an IB route to active pharmaceutical ingredients to replace current processes manufactured through traditional chemical manufacturing techniques.
A consortium comprising Shasun, Prozomix and CatSci has been established as part of the Innovate UK’s IB Catalyst. The key goal of the 9-month project is to develop a novel IB route to a nutraceutical that is currently manufactured through traditional chemical manufacturing techniques or isolated from scarce natural resources. A successful project will allow the consortium to compete with manufacture in low-cost economies and help ensure that production of this critical nutraceutical continues in the United Kingdom.
For further details of exciting projects, to find out more about CatSci's biocatalysis capabilities or to discuss new opportunities for the exploitation of biocatalysis in chemical research, development and manufacturing, please contact Dr Ross Burn.
Innovate UK is the new name for the Technology Strategy Board, the UK’s innovation agency, an executive non-departmental public body sponsored by the Department for Business, Innovation and Skills.